Table 1.
Studies on detection of cancer associated components in blood of pancreatic cancer patients and related.
| Reference | Type of patients | Isolated component | Tests used | Rate of detection (of total patients) | Type of study |
|---|---|---|---|---|---|
| Sorenson et al.[17] | PDAC | cfDNA | PCR | N/A | KRAS mutation detection |
| Kinugasa et al[21]. | All stages | cfDNA | ddPCR | 62.5% had KRAS mutation | KRAS mutation detection |
| Sausen et al.[25] | Early stage | cfDNA | ddPCR | 43% had KRAS mutation | KRAS mutation detection |
| Tjensvoll et al.[27] | Advanced PDAC | ctDNA | PCR | 71% had KRAS mutation in treatment naïve | Longitudinal analysis |
| Cohen et al.[28] | Resectable PDAC |
ctDNA | PCR based Safe-Sequencing System | KRAS mutation detection and biomarkers (including CA19–9, CEA, HGF, OPN) | |
| Lee et al.[29] | Early stage pancreatic cancer patients | ctDNA | PCR based Safe-Sequencing System | 90.5% (22/37 pre And 13/35 post operation) had KRAS mutation | Pre- and post- operation |
| Allenson et al.[54] | Localized locally advanced metastatic PDAC | ctDNA exosomes | ddPCR | 46%, 31%, and 58%, respectively had KRAS mutation in ctDNA (KRAS) 67%, 80%, and 85%, respectively, had KRAS mutation in exoDNA |
Reliability of ctDNA and exoDNA |
| Yang et al.[55] | PDAC Chronic pancreatitis Intraductal papillary mucinous neoplasia |
exosomes | ddPCR | 40% had KRAS mutation 55% (5/9) 14% (1/7) |
KRAS and TP53 detection |
| Castillo et al.[46] | PDAC | exosomes | ddPCR and Liquid chromatography−mass spectrometry | 44% using UC (KRAS) 73 % using pulldown methods (KRAS) |
KRAS detection and Exosome surface proteins |
| Bernard et al.[56] | Localized and metastatic pancreatic cancer | ctDNA exosomes | ddPCR, Next Generation Sequencing | Refer to paper | Prognostic and predictive utility of mutant nucleic acids in patients under therapy, KRAS detection |
| Allard et al.[81] | Pancreatic cancer | CTCs | CellSearch | 37.5% (6/16) had CTCs | CTC detection based on antibodies |
| Nagrath et al.[72] | Pancreatic cancer | CTCs | CTC-Chip | 100 % had CTCs | CTC detection based on antibodies |
| Khoja et al.[84] | PDAC | CTCs | ISET CellSearch |
93% had CTCs 40% had CTCs |
CTC detection based on size |
| Effenberger et al.[86] | PDAC | CTCs | magnetic-activated cell sorting enrichment technology | 33% (23/69) had CTC | CTC detection based on antibodies |
| Kulemann et al.[88] | Localized and advanced PDAC | CTCs | ScreenCell filtration and ddPCR | 72% (44/58) had CTCs 42% (11/26) had KRAS mutation |
CTC detection based on size and genomic analysis of CTCs |